Systemic Treatment of Prostate Cancer

Edited by Alan Horwich

Oxford Oncology Library

Written in a practical style that has direct clinical application for healthcare professionals
Use of "Key Points" at the start of each chapter and "Key References" at the end
Portable for quick user-friendly reference

Systemic Treatment of Prostate Cancer

Edited by Alan Horwich

Description

Prostate cancer is one of the commonest cancers in men in the western world, and the prevalence is rising currently due to improvements in screening and treatment. Serum PSA represents a useful marker of disease. It has frequently a long natural history, creating the opportunities for multiple sequential therapeutic interventions. For patients with high risk local disease or with metastases, endocrine therapy is central to management. Hormone ablation has long been the mainstay of endocrine therapy in this group of patients, though anti-androgens, oestrogens, and corticosteroids can also cause remissions. In recent years effective and well-tolerated chemotherapy regimens have been developed and evaluated. Docetaxel has an established role, and a range of biologically-targeted agents are in development.

The dominant pattern of metastatic spread is to the axial skeleton and most symptomatic care is directed to palliation of bone pain. The role of bisphosphonates remains controversial, but bone-directed isotopes such as Strontium-89 are effective.

Part of the Oxford Oncology Library, this pocketbook summarizes the up-to-date information on the use of systemic therapies in the management of prostate cancer (early stage, metastatic disease, and treatment of "biochemical" recurrence). With contributions from leading oncologists from both Europe and the USA, the book provides a practical guide to the range of endocrine and cytotoxic therapies currently available to clinicians, as well as to other palliative anticancer strategies, and will be valuable to all health professionals involved in the management of patients with prostate cancer.

Systemic Treatment of Prostate Cancer

Edited by Alan Horwich

Oxford Oncology Library

1. Biological principles of hormone therapy, Jonathan Waxman
2. PSA as a marker of progression and response, Karim Fizazi
3. Neoadjuvant and adjuvant hormone therapy for high-risk localized disease, Mike D. Shelley and Malcolm D. Mason
4. Systemic treatment of recurrence after local therapies, Stephen Freedland
5. First-line hormone therapy for metastatic prostate cancer, Ajjai S. Alva and Maha Hussain
6. Second- and third-line hormone therapies, Wolfgang Lilleby and Sophie Fossa
7. Chemotherapy for metastatic prostate cancer, Cora N. Sternberg and Fabio Calabro
8. The role of bisphosphonates in prostate cancer, Alan Horwich and David P. Dearnley
9. Systemic isotope therapy of bone metastasis, Christopher C. Parker
10. The development of biologically targeted agents, Shahneen Sandhu and Johann DeBono

Systemic Treatment of Prostate Cancer

Edited by Alan Horwich

Oxford Oncology Library

Author Information

Alan Horwich is Professor of Oncology at the Royal Marsden Hospital and Institute of Cancer Research, Sutton, UK.

Contributors:

Ajjai S. Alva, Division of Hematology-Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
Fabio Calabro
Johann DeBono, Senior Lecturer and Consultant in Oncology, Section of Medicine, Institute of Cancer Research, Royal Marsden Hospital, Drug Development Unit, Sutton, UK
David P. Dearnley, Consultant in Oncology, The Royal Marsden Hospital and Institute of Cancer Research, Surrey, UK
Sophie Fossa, Departments of Clinical Radiotherapy and Oncology, The Norwegian Radium Hospital, University of Oslo
Oslo, Norway
Karim Fizazi, Head of the Department of Medicine and Chairman of the GU Oncology Group, Institut Gustave Roussy,
Villejuif, France
Stephen Freedland, Associate Professor of Urology and Pathology and Director of Outcomes and Translational Research
Urological Surgery, Duke University Medical Center, Durham, North Carolina, USA
Alan Horwich, Professor of Oncology, The Royal Marsden Hospital and Institute of Cancer Research, Sutton, UK
Maha Hussain, Professor of Medicine and Urology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, USA
Wolfgang Lilleby, Head of Urooncology and Radiation Oncologist, The Norwegian Radium Hospital, University of Oslo
Oslo, Norway
Malcolm D. Mason, Professor and Head of Urooncology and Radiation Oncologist, Cardiff University, School of Medicine, Velindre Hospital, Cardiff, UK
Danish Mazhar
Christopher C. Parker, Consultant in Oncology, The Royal Marsden Hospital and Institute of Cancer Research, Sutton, UK
Shahneen Sandhu
Mike D. Shelley
Guru Sonpavde, Texas Oncology, Baylor College of Medicine, Webster, Texas, USA
Cora N. Sternberg, San Camillo and Forlanini Hospitals, Nuovi Padiglione IV, Rome, Italy
Jonathan H. Waxman, Professor of Medical Oncology and Consultant in Oncology, Imperial College London, London, UK